Ublituximab
DAIT AIM01
Phase 2 small_molecule active
Quick answer
Ublituximab for Autoimmune Disorders is a Phase 2 program (small_molecule) at TG THERAPEUTICS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- TG THERAPEUTICS, INC.
- Indication
- Autoimmune Disorders
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active